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Available online 19 December 2016Objective: Clinical studies using serum cardiac biomarkers to investigate a circadian variation in acutemyocardial
infarct (MI) size in ST-segment elevationmyocardial infarction (STEMI) patients reperfused by primary percuta-
neous coronary intervention (PPCI) have produced mixed results. We aimed to investigate this phenomenon
using acute MI size measured by cardiovascular magnetic resonance (CMR).
Methods: Patient-level data was obtained from 4 randomized controlled trials investigating the MI-limiting ef-
fects of cardioprotective therapies in this pooled analysis. The primary analysis was performed in those patients
with no pre-infarct angina; duration of ischemia N60 min and b360 min; Thrombolysis In Myocardial Infarction
(TIMI) ﬂow pre-PPCI ≤1; TIMI ﬂow post-PPCI 3; and no collateral ﬂow.
Results: 169 out of 376 patients with CMR data met the inclusion criteria for the primary analysis. A 24-hour cir-
cadian variation in acute MI size as a % of the area-at-risk (%AAR), after adjusting for confounders, was observed
with a peak and nadir MI size in patients with symptom onset between 00:00 and 01:00 and between 12:00 and
13:00 respectively (difference from the average MI size 5.2%, 95%CI 1.1–9.4%; p = 0.013). This was associated
with a non-signiﬁcant circadian variation in left ventricular ejection fraction (LVEF) (difference from the average
LVEF 5.9%, 95%CI−0.6–2.2%, p=0.073). There was no circadian variation inMI size or LVEF in the whole cohort.
Conclusions: We report a circadian variation in acute MI size assessed by CMR in a subset of STEMI patients
treated by PPCI, with the largest and smallest MI size occurring in patients with symptom onset between
00:00 and 01:00 and between 12:00 and 13:00 respectively.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Myocardial infarct size
Cardiovascular magnetic resonanceWhat is already known about this subject?
Several studies [1–7] have shown a circadian variation inmyocardial
infarct (MI) size by cardiac enzymes according to the time of onset of
symptoms but the literature is divided regarding the timing of the
peak MI size. Some studies have shown that peak MI size occurs in pa-
tients with symptom onset between midnight and 06:00 [3,6,7] whilec Diseases Program, Duke-NUS
pore 169857, Singapore.
.J. Hausenloy).
land Ltd. This is an open access articlothers have shown peak MI size occurring in those with symptoms
onset between 06:00 and noon [1,4,5].
What does this study add?
In this study we used cardiac magnetic resonance (CMR), which is
the gold standard method for assessing MI size, and we adjusted for
the area-at-risk (AAR) and confounders. We conﬁrmed using CMR
that in a selected group of patients a circadian pattern in MI size exists
and that peak MI size occurred in those with symptom onset between
midnight and 06:00. This was associated with a non-signiﬁcant circadi-
an variation in acute left ventricular ejection fraction (LVEF).e under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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The circadian dependence in acute MI size was only observed in a
subset of patients entering RCTs. This needs to be taken into account
to make sure that the patients are adequately balanced according to
the time of symptom onset when designing future RCTs aiming to
reduce MI size. Whether this would impact on the effectiveness of
the cardioprotective therapies needs to be assessed in future larger
studies.1. Introduction
The circadian rhythm has been shown to modulate cardiovascu-
lar physiology, impacting on parameters such as heart rate and
blood pressure [8–12] via the expression of a circadian clock gene
in the heart [13,14]. A circadian oscillation has also been shown to
impact on the expression of someproteins in the pro-survival pathways
[15], and the susceptibility of the myocardium to acute ischemia/
reperfusion injury (IRI), following myocardial infarction (MI) in mam-
malian hearts [16,17].
Durgan et al. [18] reported the existence of circadian dependence in
MI size according to the time of day in amurinemodel of acutemyocar-
dial IRI. Since then, several groups have investigated whether a circadi-
an variation also exists in ST-segment elevation myocardial infarction
(STEMI) patients but the results have been conﬂicting, both in terms
of the timings for the peak and the nadir of acute MI size [1–3] and
whether the phenomenon exists at all in humans [19]. Clinical studies
investigating the circadian variation in acute MI size have assessed irre-
versible myocardial injury using serum cardiac biomarkers such as cre-
atine kinase (CK) [1–3,6], CK-MB [5], and troponin I [1,20], and have
determined the effects on left ventricular ejection fraction (LVEF) by
echocardiography [5]. Cardiovascular magnetic resonance (CMR) is
considered the gold standard for acute MI size quantiﬁcation [21–23],
the measurement of LV volumes and LVEF [23,24], and can also provide
information on the area-at-risk (AAR) [25,26], but so far it has not been
used to investigate the circadian variation in acute MI size in STEMI pa-
tients. If a circadian dependence in acute MI size is also observed by
CMR, this would be an important factor to be taken into account in
the design of future randomized controlled trials (RCTs) aiming to re-
duce MI size.
Therefore the aim of the current study was to investigate whether
there is a circadian variation in acute MI size measured by CMR in
STEMI patients reperfused by primary percutaneous coronary interven-
tion (PPCI). In order tominimize the heterogeneity of the patient popu-
lation and to remove potential confounders for acute MI size, the
primary analysis was performed using a pre-deﬁned subset of STEMI
patients meeting speciﬁc criteria as previously described by Reiter
et al. [3]Table 1
Details of the 4 RCTs with patient level data included in this study.
Studies Country/years Intervention Patients
in study
Timing
of CMR
Area-
Ludman [27] UK/2007–2009 Erythropoietin 51 1–6 days Endoc
Crimi [28] Italy/2009–2011 Remote ischemic
conditioning of the
lower limbs
100 3–5 days T2-we
Garcia-Dorado [30] Spain/2008–2011 Adenosine 201 2–7 days T2-we
White [29] UK/2011–2012 Remote ischemic
conditioning of the
upper limb
197 3–6 days T2 ma
MI: myocardial infarct; CMR: cardiovascular magnetic resonance.2. Methods
2.1. Study population
This was a pooled analysis of patient-level data obtained from 4 published random-
ized controlled trials investigating the beneﬁt of cardioprotective therapies in STEMI pa-
tients treated by PPCI, and using acute MI size by CMR as an end-point (Table 1). The
individual methods and results for each study have been published previously [27–30]
and all studies were conducted in accordance to the Declaration of Helsinki.
2.2. Outcomes
The main outcome of interest was acute MI size by CMR, expressed as a % of the AAR
(%AAR) and LVEF. The primary exposure of interest in all analyseswas the time of day, de-
ﬁned as the time of onset of MI symptoms and recorded to the nearest minute. The prima-
ry analysis examined the effect of time as a continuous measure, using a periodic
sinusoidal function for the circadian cycle by time of symptom onset, as per the methods
of Reiter et al. [3] in a selected group of patients deﬁned by the following criteria [3]: no
pre-infarct angina (which may have inadvertently preconditioned the patients and re-
ducedMI size); duration of ischemia N60min and b360min; Thrombolysis InMyocardial
Infarction (TIMI) ﬂow pre-PPCI 0 or 1; TIMI ﬂow post-PPCI 3; and no retrograde ﬁlling of
the distal vessels (Rentrop grade 0). A secondary analysis was performed in the total un-
selected cohort of patients.
2.3. Statistical analysis
All analysis was performed using Stata version 12.1 (StataCorp, College Station,
Texas). The period of the circadian cycle was deﬁned in advance by converting time of
onset into radians using the appropriate scale. For example, to model a 24-hour period
in the circadian cycle the conversion is:
r ¼ 2π time of onset
24
ð1Þ
Then the sinusoidal function for infarct size (y) is expressed as follows:
y ¼ αþ βsin r þωð Þ ð2Þ
The parameters to be estimated were: α representing the mean infarct size; β
representing the amplitude of the rhythm; ω representing the phase of the curve, which
determines when in the circadian cycle that the maximum and minimum infarct sizes
occur.
The model in Eq. (2) was ﬁtted using trigonometric linear regression as outlined by
Cox [31]. A 24-hour period for circadian rhythm was assumed for the initial model and
then further termswere included for sinusoidal functionwith a 12-hour period. Following
ﬁtting of the model using trigonometric linear regression, the delta method was used to
provide Wald test p-values and 95% conﬁdence intervals. Analysis was also performed
by grouping patients into quartiles by time of day of onset of symptoms (00:00 to 05:59,
6:00 to 11:59, 12:00 to 17:59, 18:00 to 23:59).
The following confounders for MI size were adjusted for in the primary analysis: orig-
inating study, intervention (control, erythropoietin, remote ischemic conditioning upper
limb or lower limb, adenosine); baseline demographic characteristics such as age and gen-
der; onset to balloon time; risk factors (smoking; diabetes; hypertension; dyslipidemia;
family history of coronary artery disease); and infarct related artery. For the secondary
analysis, adjustment was made for these additional confounders: pre-infarct angina;
TIMI ﬂow pre-PPCI; presence of collateral ﬂow; and TIMI ﬂow post-PPCI.at-risk Acute MI size Outcome
ardial surface area 10 min after 0.2 mmol/kg
Dotarem,
Erythropoietin failed to reduce
MI size
ighted imaging 15 min after 0.2 mmol/kg
Magnevist
Reduction in enzymatic MI size in
the intervention arm.
Under-powered to see a
difference in MI size by CMR
ighted imaging 10 min after 0.2 mmol/kg of
Magnevist
No difference in acute MI size in
the whole cohort
pping 10 min after 0.1 mmol/kg of
Dotarem
27% reduction in MI size by CMR
in the intervention arm
Table 2
Patients' characteristics for the whole cohort.
Total number of patients
(n = 376)
Trials
Ludman [27] 40 (11%)
Crimi [28] 76 (20%)
Garcia-Dorado [30] 177 (47%)
White [29] 83 (22%)
Randomization
Intervention 191 (51%)
Placebo 185 (49%)
Age 59 ± 12
Sex —male 193 (51%)
Risk factors
Smoking 221 (59%)
Hypertension 166 (44%)
Dyslipidemia 117 (31%)
Diabetes Mellitus 55 (15%)
Family history of CAD 72 (19%)
Pre-infarct angina 108 (29%)
Onset to balloon time/min 215 ± 97
Artery involved
LAD 211 (56%)
RCA 71 (19%)
Cx 94 (25%)
TIMI ﬂow pre-PPCI
0 365 (97%)
1 11 (3%)
Rentrop collateral ﬂow
0 287 (76%)
1 61 (16%)
2 28 (7%)
TIMI ﬂow post-PPCI
1 1 (1%)
2 43 (11%)
3 330 (88%)
CMR details
LVEDV 154 ± 36
LVESV 78 ± 31
LVEF 50 ± 11
MI size/%LV 22 ± 11
AAR/%LV 33 ± 12
MI size/%AAR 64 ± 21
MVO/% 111 (53%)
CAD: coronary artery disease; LAD: left anterior descending artery; RCA: right coronary
artery; Cx: circumﬂex artery; TIMI: Thrombolysis InMyocardial Infarction; PPCI: prima-
ry percutaneous coronary intervention; LVEDV: left ventricular end diastolic volume;
LVESV: left ventricular end systolic volume; LVEF: left ventricular ejection fraction;
AAR: area at risk; LV: left ventricle; MVO: microvascular obstruction.
151H. Bulluck et al. / International Journal of Cardiology 230 (2017) 149–1543. Results
Acute CMR data were available in 376 patients and 169 patients met
the inclusion criteria for the primary analysis. Fig. 1 shows the distribu-
tion of patients in the primary analysis and for thewhole cohort accord-
ing to the time of symptom onset. Data on the baseline demographics,
angiographic and CMR ﬁndings of the whole cohort is provided in
Table 2. Table 3 provides further details between those not included
(n = 207) and included (n = 169) in the primary analysis. Apart from
the selection criteria used, the other notable differences between pa-
tients in the primary analysis when compared to those not included in
the primary analysis were: more patients from Ludman et al. [27] and
White et al. [29] and less patients from Garcia-Dorado [30]; more
males; less smokers; and more right coronary artery territory MI and
less circumﬂex territory MI.
3.1. AAR and circadian rhythm
In the unadjusted analysis, there was evidence of a 24-hour cycle
circadian variation in AAR with the difference between natural log of
average and the peak value estimated as 0.07 (95% CI 0.01 to 0.12,
p = 0.027). After adjusting for confounders, there was no longer evi-
dence of a circadian rhythm in the AAR with the difference between
natural log of average and peak values of 0.03 (95% CI−0.02 to 0.08,
p= 0.27). When a 12-hour cycle of circadian dependence was consid-
ered, there was no evidence of a circadian variation in AAR.
3.2. Primary analysis
There was evidence for a 24-hour cycle in MI size as %AAR after
adjusting for confounders with the maximumMI size being 5.2% larger
than the average MI size (95 CI 1.1 to 9.4%, p = 0.013) (Fig. 2). The MI
size was the largest for symptom onset between 00:00 and 01:00, and
the smallest for symptom onset between 12:00 and 13:00. There was
no evidence for a 12-hour circadian rhythm in MI size expressed as
%AAR (for adjusted model: maximum MI size being 3.3% larger than
the average, 95% CI −0.6 to 7.2%, p = 0.10). When patients were
grouped into quartiles by time of day of onset of symptoms (00:00 to
05:59, 6:00 to 11:59, 12:00 to 17:59, 18:00 to 23:59), the largest MI
size occurred in the 00:00 to 05:59 group (Fig. 3a) and therewas no sig-
niﬁcant difference in the duration of symptoms by quartiles to account
for that (Fig. 3b).Fig. 1.Distribution of patients according to time of onset of symptoms: (a) primary groupof 169 patients; (b)whole cohort. As expected, signiﬁcantlymore patientswere recruited in these
RCTs with time of symptom onset occurring during daytime.
Table 3
Patients' characteristics for those in the primary analysis compared to those not in the
primary analysis.
Patients not in primary
analysis
n = 207
Patients in primary
analysis
n = 169
p value
Trials
Ludman [27] 12 (30%) 28 (70%) b0.001
Crimi [28] 39 (51%) 37 (49%)
Garcia-Dorado [30] 131 (74%) 46 (26%)
White [29] 25 (30%) 58 (70%)
Randomization
Intervention 107 (56%) 84 (44%) 0.39
Placebo 100 (54%) 85 (46%)
Age 58 ± 12 59 ± 11 0.16
Sex —male 80 (42%) 113 (58%) b0.001
Risk factors
Smoking 134 (61%) 87 (39%) 0.006
Hypertension 91 (55%) 75 (45%) 0.51
Dyslipidemia 62 (53%) 55 (47%) 0.33
Diabetes mellitus 30 (55%) 25 (45%) 0.52
Family history of CAD 41 (57%) 31 (43%) 0.41
Onset to balloon time/min 235 ± 118 192 ± 64 b0.001
Artery involved
LAD 114 (54%) 97 (46%) 0.36
RCA 31 (44%) 40 (56%) 0.02
Cx 62 (66%) 32 (34%) 0.009
CMR details
LVEDV 155 ± 39 153 ± 33 0.51
LVESV 81 ± 34 75 ± 25 0.56
LVEF 49 ± 11 52 ± 11 0.054
MI size/%LV 22 ± 12 22 ± 10 0.95
AAR/%LV 34 ± 13 32 ± 11 0.25
MI size/%AAR 63 ± 20 66 ± 21 0.08
MVO/% 111 (53%) 98 (47%) 0.23
CAD: coronary artery disease; LAD: left anterior descending artery; RCA: right coronary ar-
tery; Cx: circumﬂex artery; TIMI: Thrombolysis In Myocardial Infarction; PPCI: primary
percutaneous coronary intervention; LVEDV: left ventricular end diastolic volume;
LVESV: left ventricular end systolic volume; LVEF: left ventricular ejection fraction; AAR:
area at risk; LV: left ventricle; MVO: microvascular obstruction.
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group both before and after adjusting for confounders (unadjusted
model: difference between average and peak LVEF 6.0%, 95% CI−0.6
to 12.6%, p = 0.074; adjusted model: difference between average and
peak LVEF 5.9%, 95% CI−0.6 to 12.23%, p= 0.073).Fig. 2. Circadian variation inMI size as a percentage of the AAR in the subset of patients in
the primary analysis. The peak MI size/%AAR occurred between 00:00 and 01:00 and the
nadir occurred between 12:00 and 13:00. * denotes statistical signiﬁcant with a p value
of b0.05.3.3. Secondary analysis — whole cohort
WhenMI sizewas expressed as %AAR, therewasno evidence of a 24-
hour cycle of circadian dependence forMI size (%AAR) both in the unad-
justedmodel (difference between the average andpeak value: 1.8%, 95%
CI−1.2 to 4.9%; p = 0.24) and after adjusting for confounders (differ-
ence between the average and peak value: 2.7%, 95% CI−0.1 to 5.5%;
p= 0.06). When a 12-hour cycle of circadian dependence was consid-
ered, therewas no evidence of a circadian variation inMI size expressed
as a percentage of the AAR.
When considering LVEF, there was no evidence of a 24-hour cycle of
circadian variation both in the adjusted and unadjusted analysis. When
a 12-hour circadian cycle was considered, there was evidence of a circa-
dian variation in LVEF in the unadjusted analysis (difference between
the average and the peak value was estimated as 2.2%, 95% CI 0.7 to
3.8%; p = 0.006). After adjusting for confounders, there was a non-
signiﬁcant difference in circadian variation in LVEF (difference between
the average and peak value: 1.1%, 95% CI−0.2 to 2.5%; p= 0.092).
4. Discussion
Our study shows that in a selected group of 169 patients in whom
confounders (including duration of symptoms) for acute IRI and MI
size were minimized, there was evidence of a 24-hour circadian varia-
tion in acute MI size after adjusting for the AAR. The greatest acute MI
size occurred in STEMI patients with symptom onset between 00:00
and 01:00 and the nadir was in those with symptom onset between
12:00 and 13:00. The mean difference between the peak and nadir MI
size (%AAR) was 10.4%, corresponding to 3.5% of the LV. When dividedFig. 3. (a) MI size as a percentage of the AAR in the subset of patients in the primary
analysis divided into quartiles of time of onset of symptoms; (b): comparison of
duration of symptoms according to quartiles of time of onset of symptoms. The largest
MI size occurred in the 00:00 to 05:59 group and there was no difference in the
duration of symptoms in the 4 quartiles. * denotes statistical signiﬁcant with a p value of
b0.05.
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This 24-hour circadian variation in acute MI size was associated with a
non-signiﬁcant change in LVEF. However, there was no evidence of a
circadian variation in acute MI size in the unselected cohort of 376
STEMI patients, after accounting for the AAR and confounding factors.
Following the initial work by Durgan et al. [18] who showed that
acute MI size was largest in the sleep-to-wake transition and this phe-
nomenon was abolished in cardiomyocyte-speciﬁc circadian clock mu-
tant rodents [18], the clinical studies have shown inconsistent results
as summarized in Table 4. Our ﬁndings are in keeping with Reiter
et al. [3] that showed a peak MI size occurring at 01:00. Furthermore,
2 multicentre studies (Seneviratna et al. [6] and Mahmoud et al. [7])
showed that the peakMI size occurred in thosewith symptomonset be-
tween midnight and 06:00 and this was conﬁrmed in our study. On the
other hand, 3 other studies (Suarez-Barrientos et al. [1], Fournier et al.
[4] and Ari et al. [5]) have shown that the peak MI size occurred in
those with symptom onset between 06:00 and noon. However,
Suarez-Barrientos et al. [1] used a 12-hour cycle and a second peak
was also observed in the 18:00 to midnight group. Fournier et al. [2]
subsequently reported in a multi-centre Swiss study of 6233 patients
[2] that the peak CK occurred in patients with symptom onset at
23:00 and the risk of death was the highest for those with symptom
onset at 00:00. In terms of clinical outcomes, Seneviratna et al. [6] also
showed a similar pattern in the incidence of acute heart failure and 1-
year mortality rate whereas Mahmoud et al. [7] did not ﬁnd the time
of symptom onset to be a signiﬁcant predictor of 1-year mortality in
an equally large number of patients. In a multicentre international col-
laborative study of 1099 patients from China, Scotland and Italy,
Ammirati et al. [19] showed a circadian variation in STEMI incidence
but there was no evidence of a circadian variation in MI size based on
the time of symptom onset measured by CK but half of the patients in
this study received thrombolysis or were not revascularized.
All the above previous clinical studies have the limitations of using
cardiac enzymes to measure peak MI size, with 6 out of 9 studies
using creatine kinase (CK). CK has a high sensitivity to detectmyocardi-
al necrosis but has a low speciﬁcity [32]. Furthermore, cardiac enzyme
levels in general are dependent on the timing of performing the test
and some of these studies were retrospective studies [2,6,7] and there-
fore it was highly unlikely that the cardiac enzymes were performed at
pre-speciﬁed times. Furthermore the choice (thrombolysis versus PPCI)
[33] and the success of reperfusion strategy can inﬂuence the release of
cardiac enzymes into theblood stream. CMR is considered the gold stan-
dard for the accurate quantiﬁcation of acute MI size [21–23]. CMR pro-
vides additional information on the AAR, and it was difﬁcult to
account for that in the previous studies using cardiac enzymes alone.
Reiter et al. [3] only included a subgroup of patients with CMR (n =
45) and CK was used to assess for a circadian variation in MI size for
their whole cohort. Our study is the ﬁrst to use CMR to measure acuteTable 4
Summary of clinical studies investigating onset of symptoms and circadian variation of MI size
Studies Country/years Patients in study Surroga
Suarez-Barrientos [1] Single centre — Spain 811 CK
TnI
Reiter [3] Single centre — United States 165 CK
Arroyo-Ucar [20] Single centre — Spain 108 TnI
Fournier [4] Single centre — Switzerland 353 CK
Ammirati [19] Multicentre — Italy, Scotland, and China 1099 CK
Fournier [2] Multicentre — Switzerland 6223 CK
Seneviratna [6] Multicentre — Singapore 6710 CK
Mahmoud [7] Multicentre — Netherlands 6799 CK
Ari [5] Single centre — Turkey 252 CK-MB
CK: creatine kinase; TnI: troponin I; CK-MB: creatine kinase-myocardial band; MI: myocardialMI size as a percentage of the AAR and explore the circadian rhythm ac-
cording to the time of onset of symptoms and therefore we believe that
our ﬁndings are more robust that previous studies. We have found that
there was a 24-hour circadian variation in acute MI size depending on
time of symptom onset in a subset of patients entering RCTs in the cur-
rent era in a three-centre European (England, Italy and Spain) collabora-
tive study. We did not ﬁnd any signiﬁcant circadian variation in a 12-
hour cycle as previously shown [1] after adjusting for confounders.
Our ﬁndings are consistent with the current belief that the circadian
clocks are composed of proteins that generate self-sustaining,
transcriptionally-based mechanisms of positive and negative feedback
loops with a free-running period of approximately 24 h [34] rather
than 12 h. There are several other factors that can affect MI size in the
clinical setting (pre-infarct angina, onset to balloon time, co-
morbidities, TIMI ﬂow pre- and post-PCI and collateral ﬂow) and failure
to carefully adjust for these confounders may explain the conﬂicting
ﬁndings between those from our study, Reiter et al. [3], Seneviratna
et al. [6] and Mahmoud et al. [7] and those from Suarez-Barrientos
et al. [1], Fournier et al. [4]and Ari et al. [5]. Furthermore, as a result of
these multiple confounders of MI size, the circadian variation in MI
size may not be clinically relevant for most patients. The recent large
study by Mahmoud et al. [6] showed no impact on 1-year mortality.
Our study showed that the extent of variation in MI size by CMR did
not signiﬁcantly inﬂuence acute LVEF and the likely explanation is
that the difference between the peak and nadir MI size of 10.4% of the
AAR was too small to affect the LV volumes signiﬁcantly for the cohort
as a whole but would likely be important for those with a large AAR.
Our sample size was too small to only look at the circadian variation
of LVEF in those patients with a large AAR and warrants further investi-
gation in future studies AAR.
4.1. Limitations
This was a retrospective study and patient level data was obtained
from 4 RCTs and therefore may not be a true representation of the
STEMI cohort presenting to hospital. However, this is representative of
patients entering RCTs in the current era. The sample size in the primary
analysis group was b50% of the original cohort but this was similar to
the sample reported by Reiter et al. (n = 165) [3]. Patients were ran-
domized to an intervention arm or placebo but we have adjusted for
these factors in our analysis. We only included patients from one conti-
nent unlike the study by Ammirati et al. [19] but despite this, the time
zone geographically may have some subtle differences among these 3
countries andwe did not account for that. Themodality used to quantify
the AAR by CMR was different in the 4 studies and the contrast agents
used for late gadolinium enhancement were varied as shown in
Table 1. We did not have clinical outcomes on these patients. Our sam-
ple sizewas small and the cardioprotective therapies in the 4 RCTswerein STEMI.
te for MI size Outcome
Peak MI size between 06:00 and noon
Peak MI size 01:00 onset of ischemia and 05:00 onset of reperfusion
Peak MI size between 00:00 and 12:00
Peak MI size between 00:00 and 05:59.
Peak MI incidence from 06:00 to noon.
No clear-cut circadian dependence of MI size
Peak MI size at 23:00, whereas the nadir MI size was at 11:00. Risk of
death from STEMI was the highest at 00:00 and lowest at 12:00
Peak MI size and incidence of acute heart failure from midnight to
06:00 and nadir from 06:00 to noon
Peak MI size around 03:00 and nadir around 11:00
Peak MI size and poor LV function by echocardiography occurred
in the 06:00–noon period
infarction; LV: left ventricle.
154 H. Bulluck et al. / International Journal of Cardiology 230 (2017) 149–154different. Therefore we were not able to assess whether the effective-
ness of cardioprotective therapies also had a circadian dependence in
this subset of patients depending on the time of day and this needs to
be assessed in future larger studies.
5. Conclusions
We have shown that a circadian variation in acute MI size assessed
by CMR according to the time of symptom onset exists in a speciﬁc
group of patients, after adjusting for confounders of MI size. The largest
and smallestMI size occurred in those patients with symptom onset be-
tween 00:00 to 01:00 and 12:00 to 13:00, respectively. This was associ-
ated with a non-signiﬁcant circadian variation in acute LVEF. The
circadian dependence in acute MI size was only observed in a subset
of patients entering RCTs. This needs to be taken into account to make
sure that the patients are adequately balanced in the 4 quartiles of
time of onset of symptoms when designing future RCTs aiming to re-
duce MI size. Whether this would impact on the effectiveness of the
cardioprotective therapies needs to be assessed in future larger studies.
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